Legend Biotech (LEGN) P/S ratio
Legend Biotech (LEGN) trades at 2.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 3.9×. That is 58.9% lower than the 9.5× of fiscal 2024. Figures as of 18 Nov 2026, 07:04 UTC, from Yahoo Finance.
Key facts
- P/S ratio today
- 2.9×
- P/S ratio, fiscal 2025
- 3.9×
- Change on fiscal 2024
- −58.9%
- Highest on record
- 67.9×fiscal 2022
- Lowest on record
- 3.9×fiscal 2025
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Legend Biotech P/S ratio, in more detail
Today's figure is 25.9% below the fiscal 2025 year-end.
Across the 4 fiscal year-ends on record (2022–2025), the highest was 67.9× in fiscal 2022 and the lowest 3.9× in fiscal 2025. Today's P/S ratio is at or below every one of the 4 fiscal year-ends on record; their median is 23.3×.
P/S ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Legend Biotech P/S ratio, year by year
| Fiscal year | P/S ratio | Change | Year ended | Share price at year-end | Revenue per share |
|---|---|---|---|---|---|
| Today | 2.9× | — | $16.11 | — | |
| 2025 | 3.9× | 58.9% down | $21.74 | $5.58 | |
| 2024 | 9.5× | 74.5% down | $32.54 | $3.43 | |
| 2023 | 37.2× | 45.2% down | $60.17 | $1.62 | |
| 2022 | 67.9× | — | $49.92 | $0.74 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
How to read it
It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.
Legend Biotech, figure by figure
- Legend Biotech market cap
- Legend Biotech revenue
- Legend Biotech earnings
- Legend Biotech earnings per share (EPS)
- Legend Biotech P/E ratio
- Legend Biotech P/B ratio
- Legend Biotech free cash flow
- Legend Biotech operating margin
- Legend Biotech dividend
- Legend Biotech shares outstanding
- Legend Biotech total debt
- Legend Biotech cash on hand
- Legend Biotech total assets
- Legend Biotech return on equity (ROE)
- Legend Biotech return on invested capital (ROIC)
Legend Biotech (LEGN) overview: price, valuation and scorecardAll health care companies by market value
Legend Biotech P/S ratio: questions and answers
What is Legend Biotech's P/S ratio?
Legend Biotech (LEGN) trades at 2.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 3.9×. That is 58.9% lower than the 9.5× of fiscal 2024.
Is Legend Biotech's P/S ratio high or low compared with its own history?
Today's P/S ratio is at or below every one of the 4 fiscal year-ends on record; their median is 23.3×.
What are the highest and lowest P/S ratio figures on record for Legend Biotech?
Across the 4 fiscal year-ends on record (2022–2025), the highest was 67.9× in fiscal 2022 and the lowest 3.9× in fiscal 2025.
How is Legend Biotech's P/S ratio calculated?
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/S ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Legend Biotech (LEGN) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/LEGN/ps-ratio
Underlying data: Yahoo Finance.